Cul4A is an oncogene in malignant pleural mesothelioma

被引:58
|
作者
Hung, Ming-Szu [1 ,2 ,3 ]
Mao, Jian-Hua [4 ]
Xu, Zhidong [1 ]
Yang, Cheng-Ta [2 ]
Yu, Jau-Song [5 ]
Harvard, Chansonette [6 ]
Lin, Yu-Ching [2 ]
Bravo, Dawn Therese [1 ]
Jablons, David M. [1 ]
You, Liang [1 ]
机构
[1] Univ Calif San Francisco, Dept Surg, Thorac Oncol Lab, Ctr Comprehens Canc, San Francisco, CA 94115 USA
[2] Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Chiayi, Taiwan
[3] Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Tao Yuan, Taiwan
[4] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA
[5] Chang Gung Univ, Coll Med, Dept Cell & Mol Biol, Tao Yuan, Taiwan
[6] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada
关键词
Cul4A; amplification; mesothelioma; p21; p27; DEPENDENT KINASE INHIBITOR; CELL-CYCLE; BREAST-CANCER; HUMAN HOMOLOG; P27(KIP1); GENE; DEGRADATION; P27; PROTEOLYSIS; OVEREXPRESSION;
D O I
10.1111/j.1582-4934.2009.00971.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cullin 4A (Cul4A) is important in cell survival, development, growth and the cell cycle, but its role in mesothelioma has not been studied. For the first time, we identified amplification of the Cul4A gene in four of five mesothelioma cell lines. Consistent with increased Cul4A gene copy number, we found that Cul4A protein was overexpressed in mesothelioma cells as well. Cul4A protein was also over-expressed in 64% of primary malignant pleural mesothelioma (MPM) tumours. Furthermore, knockdown of Cul4A with shRNA in mesothelioma cells resulted in up-regulation of p21 and p27 tumour suppressor proteins in a p53-independent manner in H290, H28 and MS-1 mesothelioma cell lines. Knockdown of Cul4A also resulted in G0/G1 cell cycle arrest and decreased colony formation in H290, H28 and MS-1 mesothelioma cell lines. Moreover, G0/G1 cell cycle arrest was partially reversed by siRNA down-regulation of p21 and/or p27 in Cul4A knockdown H290 cell line. In the contrary, overexpression of Cul4A resulted in down-regulation of p21 and p27 proteins and increased colony formation in H28 mesothelioma cell line. Both p21 and p27 showed faster degradation rates in Cul4A overexpressed H28 cell line and slower degradation rates in Cul4A knockdown H28 cell line. Our study indicates that Cul4A amplification and overexpression play an oncogenic role in the pathogenesis of mesothelioma. Thus, Cul4A may be a potential therapeutic target for MPM.
引用
收藏
页码:350 / 358
页数:9
相关论文
共 50 条
  • [41] Malignant Pleural Effusion in Malignant Pleural Mesothelioma An Innocent Bystander?
    Muruganandan, Sanjeevan
    Duong, Victor
    CHEST, 2021, 160 (05) : 1602 - 1603
  • [42] Surgery for malignant pleural mesothelioma
    Archer, Michael A.
    Bueno, Raphael
    LUNG CANCER MANAGEMENT, 2015, 4 (05) : 231 - 241
  • [43] Chemotherapy for malignant pleural mesothelioma
    Vogelzang, Nicholas J.
    LANCET, 2008, 371 (9625): : 1640 - 1642
  • [44] Localized malignant pleural mesothelioma
    Nakano T.
    Hamanaka R.
    Oiwa K.
    Nakazato K.
    Masuda R.
    Iwazaki M.
    General Thoracic and Cardiovascular Surgery, 2012, 60 (7) : 468 - 474
  • [45] Malignant pleural mesothelioma in situ
    Ando, Kohei
    Morohoshi, Takao
    Tsuura, Yukio
    Masuda, Munetaka
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2022, 35 (05)
  • [46] Treatment of malignant pleural mesothelioma
    Alolayan, Ashwaq
    Saadeddin, Ahmed
    Bamousa, Ahmed
    Jazieh, Abdul-Rahman
    ANNALS OF THORACIC MEDICINE, 2010, 5 (05) : S71 - S75
  • [47] Malignant pleural mesothelioma: an update
    Hajj, Glaucia N. M.
    Cavarson, Carolina H.
    Lopes Pinto, Clovis Antonio
    Venturi, Gabriela
    Navarro, Joao R.
    Cordeiro de Lima, Vladmir C.
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2021, 47 (06)
  • [48] Update on Malignant Pleural Mesothelioma
    Campbell, Nicholas Paul
    Kindler, Hedy Lee
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 32 (01) : 102 - 110
  • [49] Immunotherapy in Malignant Pleural Mesothelioma
    de Gooijer, Cornedine J.
    Borm, Frank J.
    Scherpereel, Arnaud
    Baas, Paul
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [50] Pemetrexed in malignant pleural mesothelioma
    Hazarika, M
    White, RM
    Booth, BP
    Wang, YC
    Ham, DYL
    Liang, CY
    Rahman, A
    Gobburu, JVS
    Li, N
    Sridhara, R
    Morse, DE
    Lostritto, R
    Garvey, P
    Johnson, JR
    Pazdur, R
    CLINICAL CANCER RESEARCH, 2005, 11 (03) : 982 - 992